Vielight is recognized as the innovation leader in the practical applications of transcranial photobiomodulation (tPBM). TPBM is the application of low dose red or near-infrared (NIR) light to improve brain functions.
Vielight’s experimental devices are in major clinical studies for Alzheimer’s disease, Parkinson’s disease and traumatic brain injury, among others.
Vielight is also investigating the use of its tPBM devices to enhance cognitive and sports performance, as well as advanced meditation experience. The list of PBM and tPBM applications is growing, as does the scope of Vielight research and development.
In 2021 Vielight has completed recruitment for its clinical trial for COVID-19, which was commenced in 2020. The results of this trial are expected in the early fall of 2021.